IFNG and myeloid sarcoma: The treatments reduced the amount of lesions in the brain and shifted the immune response from Th1 to Th2 in a group of MS patients.111, 112 MS patients who received placebo showed low levels of APL-reactive T cell with high levels of the inflammatory cytokine, IFN-γ.112 These same observations were made for MS patients that received MBP83–99.